<DOC>
	<DOC>NCT01999699</DOC>
	<brief_summary>This study will investigate the response of the immune system to a hepatitis B (HB) vaccine in healthy adults 50 to 70 years of age. This study is partially funded by the National Institute of Allergy and Infectious Diseases.</brief_summary>
	<brief_title>A Study of the Immune Response to Heplisav in Healthy Older Adults</brief_title>
	<detailed_description>The purpose of this study is to examine how the immune system responds to vaccination with HEPLISAV.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<criteria>50 to 70 years of age, inclusive In good health in the opinion of the principal investigator, based upon medical history and physical examination Serum negative for HBsAg, antiHBs, antibody to hepatitis B core antigen (antiHBc), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) If female of childbearing potential, agree to consistently use a highly effective method of birth control from the screening visit through Week 12/Visit 10 Pregnant, breastfeeding, or planning a pregnancy Known history of an autoimmune disease Previously received any hepatitis B vaccine (approved or investigational) Bodymass index (BMI) &gt;30 kg/m2, diabetes mellitus (type 1 or 2), or other chronic medical condition that in the opinion of the principal investigator might interfere with the immune response to hepatitis B vaccination</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Heplisav</keyword>
</DOC>